Literature DB >> 17373172

Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp.

Emil Tanghetti1, Philip Werschler.   

Abstract

It is timely to compare the efficacy and tolerability of 2 actinic keratosis (AK) therapies--5% 5-fluorouracil (5-FU) cream and imiquimod cream. Thirty-six patients with 4 or more AKs were randomly assigned to receive 5% 5-FU cream twice daily for 2 to 4 weeks or 5% imiquimod cream twice weekly for 16 weeks. Five percent 5-FU was more effective than imiquimod in exposing what were presumed to be subclinical AKs, reducing the final AK count (total AK count declined during the 24-week study by 94% vs. 66%, P < .05), achieving complete clearance (incidence of 84% vs. 24% by week 24, P < .01), and achieving clearance rapidly. Tolerability was similar except for erythema, which was initially significantly higher with 5-FU than imiquimod but resolved rapidly and was significantly lower than imiquimod by week 16. Five percent 5-FU remains the gold standard field therapy for AKs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373172

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  14 in total

Review 1.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.

Authors:  Romain Neugebauer; Katherine A Levandoski; Zheng Zhu; Monica Sokil; Mary-Margaret Chren; Gary D Friedman; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2017-12-24       Impact factor: 11.527

Review 3.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study.

Authors:  Dow Stough; Alicia D Bucko; George Vamvakias; Elyse S Rafal; Steven A Davis
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

5.  Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.

Authors:  William Philip Werschler
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

6.  Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.

Authors:  E Bart Tarbet; Deanna Larson; Bentley J Anderson; Kevin W Bailey; Min-Hui Wong; Donald F Smee
Journal:  Antiviral Res       Date:  2011-03-23       Impact factor: 5.970

7.  Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.

Authors:  Romain Neugebauer; Katherine A Su; Zheng Zhu; Monica Sokil; Mary-Margaret Chren; Gary D Friedman; Maryam M Asgari
Journal:  J Am Acad Dermatol       Date:  2018-11-17       Impact factor: 11.527

8.  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

Authors:  Ralf Gutzmer; Susanne Wiegand; Oliver Kölbl; Kai Wermker; Markus Heppt; Carola Berking
Journal:  Dtsch Arztebl Int       Date:  2019-09-13       Impact factor: 5.594

Review 9.  Vitamin D and Vitamin D Analogs as Adjuncts to Field Therapy Treatments for Actinic Keratoses: Current Research and Future Approaches.

Authors:  Zafer Sattouf; Steven J Repas; Jeffrey B Travers; Craig A Rohan
Journal:  J Skin Cancer       Date:  2021-06-19

Review 10.  A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.

Authors:  Robert Sinclair; Christopher Baker; Lynda Spelman; Madeleine Supranowicz; Beth MacMahon
Journal:  Australas J Dermatol       Date:  2020-08-25       Impact factor: 2.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.